Neuren thinks big
Wednesday, 16 July, 2008
Neuren Pharmaceuticals [ASX: NEU] has concluded patient recruitment and dosing for its Phase III clinical trial of Glypromate, a therapeutic designed to reduce brain impairment after major heart surgery.
The recruitment of 320 patients has been concluded ahead of schedule, and Neuren is expecting to release provisional efficacy results before the end of the year.
Up to a third of patients suffer cognitive impairment three months after major heart surgery, and there is currently no approved treatment to prevent it.
Accurate age estimation with DNA methylation
Using cutting-edge artificial intelligence, scientists created a tool that can determine a...
Algae unlocks a more ethical way to grow cells
Researchers have combined a new type of Queensland algae, Chlorella sp. BDH-1, with...
Oral drug shows promise for treating Barth syndrome
An oral drug called MA-5 can improve both heart and muscle problems in Barth syndrome, a rare...
